Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Imfinzi Granted US Orphan Drug Designation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 02:32am EDT

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration had awarded its cancer drug Imfinzi orphan drug status as a treatment for small-cell lung cancer.

The designation is given to medicines that aim to treat rare diseases and provides benefits such as market exclusivity and faster regulatory approvals.

Imfinzi is currently approved as a treatment for inoperable stage 3 non-small-cell lung cancer after chemotherapy and radiation therapy.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.18% 758.6 Delayed Quote.12.39%
ASTRAZENECA -0.19% 6390 Delayed Quote.8.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
07/17EXCLUSIVE : Woodford biotech stakes first off block in asset sale - source
RE
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16LONDON STOCK EXCHANGE : Burberry leads FTSE 100 higher, mid-caps glide over ster..
RE
07/15ASTRAZENECA : Update on US regulatory decision for Farxiga in type-1 diabetes
PU
07/15ASTRAZENECA : Update on US regulatory decision for Farxiga
AQ
07/12UK's main index sees seventh straight day of losses, BoE comments lift midcap..
RE
07/12ASTRAZENECA : Imfinzi granted US Orphan Drug Designation for small cell lung can..
PU
07/12ASTRAZENECA : Imfinzi Granted US Orphan Drug Designation
DJ
07/12ASTRAZENECA : Imfinzi granted US Orphan Drug Designation for
AQ
07/11EUROPE : European shares dip on pharma drag as Fed optimism sizzles out
RE
More news
Financials (USD)
Sales 2019 23 679 M
EBIT 2019 6 340 M
Net income 2019 2 426 M
Debt 2019 10 940 M
Yield 2019 3,52%
P/E ratio 2019 42,3x
P/E ratio 2020 31,5x
EV / Sales2019 4,89x
EV / Sales2020 4,42x
Capitalization 105 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 84,91  $
Last Close Price 79,87  $
Spread / Highest target 42,2%
Spread / Average Target 6,32%
Spread / Lowest Target -21,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA8.80%104 798
JOHNSON & JOHNSON2.34%350 653
PFIZER-1.35%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699